As 2025 draws to a close, IDBS celebrates customer successes and key innovations that advanced scientific digital transformation--from launching IDBS Polar Control and accelerating tech transfer to ...

Physicians stand to earn big money when signing up patients for drug trials. And lately, some of those trials have been ...

Intellicule, a software company founded and led by Purdue University researchers, will use an SBIR Phase I grant from the NIH to develop software technology that could impact precision medicine. The ...

With the advent of AI-powered protein design tools, protein-based therapeutics may no longer be constrained by the limits imposed by natural selection.

During the last week, Cathie Wood’s ARK Invest reported strong buying in biotech, genomics, and deep-tech names across its various funds while reducing exposure in diagnostics, software chips, and ...

Oct 28 (Reuters) - Medical equipment maker Thermo Fisher (TMO.N), opens new tab is nearing an all-cash takeover of U.S-based Clario in a deal that could value the clinical trial data management ...

BARCELONA, Spain — An experimental drug that takes a novel approach to protecting injured brain cells has shown promising results in an early Phase 2 trial of patients with acute ischemic stroke (AIS) ...

Dianthus Therapeutics and Boehringer Ingelheim headlined the latest round of licensing deals featuring Chinese biotechs. Fierce's deep dive into the dispute between Novo Nordisk and KBP Biosciences ...

Oct 14 (Reuters) - U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical (4502.T), opens new tab, deepening their ...

After walking away from cell therapy and narrowing its focus to just three modalities, Takeda is doubling down on its remaining strategic commitment by reupping a pact with AI drug designer Nabla Bio.